Quiver Bioscience advances Nav1.7 antisense therapy as pain drug innovation heats up
Chronic pain needs safer drugs. Quiver’s NIH-backed Nav1.7 ASO bet could test whether genetics can beat opioid-era limits.
Pharma & Biotech
Pharma & Biotech
Quiver Bioscience deal shows how Angelini Pharma is rethinking genetic epilepsy innovation
Angelini Pharma partners with Quiver Bioscience to discover new genetic epilepsy targets. Find out what this changes for drug discovery and patients.